

TREATMENT OF CHRONIC HEPATITIS C INFECTION IN THALASSEMIA AND HEMOPHILIA PATIENTS; A CASE SERIES STUDY

MOHAMMAD REZA FATAHI 1

Department of Gastroenterology, Shiraz University of Medical Sciences, Shiraz, Iran

ABSTRACT

Background: Repeated blood and blood products transfusion is the essential part of treatment of major Thalassemia and hemophilia patients and is associated with increased risk -of transmission of blood born viruses, such as I-IBV, HCV, HIV, etc. between the individuals.

Materials and Methods: Sixty-three HCV infected Thalassemia and hemophilia patients, who had been enrolled in-Shiraz Hepatitis Registry Center, were entered in an antiviral treatment program consisting of pegylated interferon α -2a, 135-180 ug subcutaneously injected once a week and ribavirin 600-1000 mg orally administered per day, which was adjusted with genotype, body weight, and. hemoglobin level. The treatment continued for 24 weeks for genotypes 2 and 3 and 48 weeks for genotype 1.

Results: Genotype 1 (57%) followed by genotype III (38%) were the most common genotypes among our patients. In 47 patients for whom treatment was prescribed, 41 ones had end of treatment response (87%), including 21 out of 24 (87%) thalassemia and 20 out of 23 (87%) hemophilia patients. The end of treatment response rates were 100% in genotype 2 and 3 (23 cases) and 75% (18/24 cases) in genotype 1. Overall, sustained virologic response (SVR) were 41%, with 43% (9/21 cases) in Thalassemia and 40% (8/20 cases) in hemophilia patients, 4 cases of whom had genotype 1 infection (21%) and 13 had genotype 2 and 3 infection (59%).

Conclusion: HCV infected major Thalassemia and hemophilia patients who have been treated with combined IFN α -2a and ribavirin achieved end of treatment response better than other HCV infected subjects in this study

KEYWORDS: Treatment of Chronic Hepatitis C Infection in Thalassemia and Hemophilia Patients; A Case Series Study, Genotype III